Recently, carlumab (CNTO-888), an CCL2 neutralizing antibody, was tested in Phase 2 clinical trials in patients with metastatic castration-resistant PC (NTC00992186) (55). The gene discussed is CCL2; the disease is pachyonychia congenita.